The Assistance Fund Opens New Program for Colorectal Cancer
Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Colorectal Cancer ORLANDO, FLORIDA / ACCESS Newswire...
Cancer
Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity
Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly...
Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity
Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly...
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP...
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire /...
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer
Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026...
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal...
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy aloneElraglusib...
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential-...
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and...
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12,...
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds...
Polarean Highlights New CHEST Journal Study Demonstrating Xenon MRI Predicts Cystic Fibrosis Exacerbations
Findings Show Xenon MRI Ventilation Defects Independently Predicts Exacerbation Risk Beyond Conventional Clinical Measures New CHEST Journal Study Demonstrates Xenon...
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact...
CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz’s Team and an “Evidence Sprint 2026” Focused on Grants, Research and Clinical Evidence
Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on...
CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz’s Team and an “Evidence Sprint 2026” Focused on Grants, Research and Clinical Evidence
Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on...
CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz’s Team and an “Evidence Sprint 2026” Focused on Grants, Research and Clinical Evidence
Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on...
Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record levelsHOUSTON, TX, Jan. 10, 2026...
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in...
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
- Rapidly transforming into a leading global biopharma companyCOPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:...